News about Global Pharma

Intas Pharma Appoints Udit Sakhuja as Senior General Manager-Global New Product Launch

Prior to joining Intas, Sakhuja served at Dr. Reddy's Laboratories for over four years, where he held key leadership roles including Head of Marketing for Rheumatology and Ortho Biologics & Pain Management Portfolio, as well as Head of Marketing for NBE/NCE Innovative Oncology Assets.

Global Pharma | 02/07/2025 | By Manvi |  354

Regulus Becomes Wholly Qwned Subsidiary of Novartis

Novartis has successfully completed its acquisition of Regulus Therapeutics Inc. (Regulus), which has now become an indirect, wholly owned subsidiary of the Swiss pharmaceutical company.

Global Pharma | 02/07/2025 | By Manvi |  167

Aurobindo's Lyfius Pharma Resumes Penicillin-G Production at Kakinada Plant

Lyfius Pharma, a wholly owned subsidiary of Aurobindo Pharma, has resumed Penicillin-G production after receiving the green light from the Andhra Pradesh Pollution Control Board (APPCB) to operate the Kakinada plant, which had been temporarily paused following a fire in April.

Global Pharma | 01/07/2025 | By Manvi |  1793

Fresenius Kabi Launches FDA Approved Denosumab Biosimilars in US

These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia® (denosumab) and Xgeva® (denosumab), respectively.

Global Pharma | 01/07/2025 | By Manvi |  312

Torrent Pharma to Acquire Controlling Stake in JB Pharma from KKR in INR 25,689 Crore Deal

Torrent Pharmaceuticals has announced plans to acquire a controlling stake in JB Pharma from KKR in an INR 25,689 crore deal, paving the way for a merger that will significantly boost its Indian market position and global expansion strategy.

Global Pharma | 01/07/2025 | By Mrinmoy Dey |  528

Biocon Biologics Scales Up Insulin Access in Malaysia

Biocon Biologics has announced that its Malaysian subsidiary has crossed the milestone of supplying over 100 million recombinant human insulin cartridges to Malaysia’s Ministry of Health, reinforcing its commitment to affordable and accessible diabetes care.

Global Pharma | 30/06/2025 | By Mrinmoy Dey |  365

Cycle Pharmaceuticals' HARLIKU Gets FDA Approval

Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction of urine homogentisic acid (HGA) in adult patients with AKU.

Global Pharma | 30/06/2025 | By Manvi |  157

FDA Clears Archeus' IND for Prostate Cancer Therapy ART-101

Archeus Technologies announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule that Archeus has developed for the imaging and treatment of prostate cancer.

Global Pharma | 30/06/2025 | By Manvi |  301

Alembic Pharmaceuticals Secures USFDA Final Approval for Doxorubicin Hydrochloride Liposome Injection

Alembic Pharmaceuticals has received final USFDA approval for its generic Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials, for the treatment of Ovarian Cancer, AIDS-Related Kaposi’s Sarcoma, and Multiple Myeloma.

Global Pharma | 30/06/2025 | By Manvi |  260

Ancora Heart Hits Enrollment Goal in CORCINCH-HF Trial for HFrEF Therapy

Ancora Heart, Inc. announced that it has reached the first enrollment milestone in the CORCINCH-HF pivotal trial evaluating the AccuCinch® Transcatheter Left Ventricular Restoration System in patients with heart failure with reduced ejection fraction (HFrEF).

Global Pharma | 27/06/2025 | By Manvi |  168